InsiderTrades.com logo
Peng Lu net worth and biography
  • LinkedIn
  • Phone
  • Email
  • Website

Peng Lu Biography and Net Worth

Chief Medical Officer of Pharvaris

Dr. Lu joined the Company in 2020, bringing 15 years of protein therapeutics and small molecule drug

development experience including within genetic rare diseases. Previously, Dr. Lu served as the Vice President, Global Program Lead for rare diseases at Takeda (via acquisition of Shire). During Dr. Lu’s time at Takeda/Shire, she was instrumental in leading project teams that successfully completed two Phase 3 pivotal HAE studies and achieved global approval of TAKHZYRO (lanadelumab-flyo) for the prevention of HAE attacks in the U.S., EU, and the rest of world. In addition, she has also led the life-cycle management of TAKHZYRO beyond HAE, looking to broaden indications in other plasma-kallikrein-mediated diseases.

Prior to Takeda/Shire, Dr. Lu held roles in clinical development, translational research and clinical pharmacology with increasing levels of responsibility at AbbVie and Roche/Genentech, where she was responsible for the design and implementation of early and late development clinical strategy across a broad range of indications including autoimmune, respiratory, and genetic diseases leading to multiple approvals. Dr. Lu received her medical degree from Beijing Medical University and Ph.D. from The University of Texas, Austin, in systems biology.

What is Peng Lu's net worth?

The estimated net worth of Peng Lu is at least $1.89 million as of April 23rd, 2026. Dr. Lu owns 66,083 shares of Pharvaris stock worth more than $1,891,956 as of April 27th. This net worth estimate does not reflect any other assets that Dr. Lu may own. Learn More about Peng Lu's net worth.

How do I contact Peng Lu?

The corporate mailing address for Dr. Lu and other Pharvaris executives is , , . Pharvaris can also be reached via phone at 31-71-203-6410 and via email at [email protected]. Learn More on Peng Lu's contact information.

Has Peng Lu been buying or selling shares of Pharvaris?

During the last ninety days, Peng Lu has sold $213,383.05 of Pharvaris stock. Most recently, Peng Lu sold 100 shares of the business's stock in a transaction on Thursday, April 23rd. The shares were sold at an average price of $30.03, for a transaction totalling $3,003.00. Following the completion of the sale, the insider now directly owns 66,083 shares of the company's stock, valued at $1,984,472.49. Learn More on Peng Lu's trading history.

Who are Pharvaris' active insiders?

Pharvaris' insider roster includes Anne Lesage (Chief Early Development Officer), Peng Lu (Chief Medical Officer), and Berndt Modig (Chief Executive Officer, Director (CH)). Learn More on Pharvaris' active insiders.

Are insiders buying or selling shares of Pharvaris?

In the last twelve months, insiders at the sold shares 9 times. They sold a total of 54,426 shares worth more than $1,578,272.67. The most recent insider tranaction occured on April, 23rd when insider Peng Lu sold 100 shares worth more than $3,003.00. Learn More about insider trades at Pharvaris.

Information on this page was last updated on 4/23/2026.

Peng Lu Insider Trading History at Pharvaris

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/23/2026Sell100$30.03$3,003.0066,083View SEC Filing Icon  
4/22/2026Sell7,001$30.05$210,380.0566,083View SEC Filing Icon  
See Full Table

Peng Lu Buying and Selling Activity at Pharvaris

This chart shows Peng Lu's buying and selling at Pharvaris by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Pharvaris Company Overview

Pharvaris logo
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.
Read More

Today's Range

Now: $28.92
Low: $28.36
High: $29.72

50 Day Range

MA: $27.43
Low: $25.34
High: $30.04

2 Week Range

Now: $28.92
Low: $14.59
High: $30.24

Volume

20,745 shs

Average Volume

170,617 shs

Market Capitalization

$1.89 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A